Elevance Health Inc. Common Stock vs Cassava Sciences Inc — how do they compare? Elevance Health Inc. Common Stock trades at $401.8 (market cap $87.68B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Elevance Health Inc. Common Stock is far larger — about 2225.4× Cassava Sciences Inc's market cap, and Elevance Health Inc. Common Stock pays a 1.7% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ELV | FLNA | |
|---|---|---|
Market Cap | $87.68B | $39.40M |
Volume | 904,657 | 759,018 |
Sector | Health | Health |
52-Week High | $426.79 | $4.64 |
52-Week Low | $280.74 | $0.68 |
Enterprise Value | $108.49B | -$43.28M |
Dividend Yield | 1.7% | — |
Typical Hold Time | — | 37 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Elevance Health provides health plans and healthcare services. Its offerings include medical, behavioral health, pharmacy, dental, vision, and complex-care solutions, including through the Carelon business.
Read more on ELV →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →